Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02407431 · ClinicalTrials.gov registry record
PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort
A clinical trial of Idiopathic Pulmonary Fibrosis, sponsored by University of Pittsburgh.
- Active
- Registry status
- 1,000
- Enrollment target
- 5
- Study locations
NCT02407431 is a study of Idiopathic Pulmonary Fibrosis that is active but no longer recruiting, run by University of Pittsburgh. The registered enrollment target is 1,000 participants, above the 732-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (37% higher). The trial reports 5 study locations across 3 states.
The verdict
NCT02407431, a study of Idiopathic Pulmonary Fibrosis, is active but no longer recruiting, sponsored by University of Pittsburgh.
- ACTIVE NOT RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of the PaTH Network IPF Clinician-Patient Partnership Cohort is to use clinical data from electronic health records (EHR) and patient reported outcomes (PRO) to answer questions of clinical importance to patients with Idiopathic Pulmonary Fibrosis, providers, and other stakeholders.
Conditions Studied
Study Locations (5)
Pennsylvania
- Jody McCullough - Hershey
- Anuradha Paranjape - Philadelphia
- University of Pittsburgh - Pittsburgh
Maryland
- Johns Hopkins University - Baltimore
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2015-03 |
| Est. Completion | 2030-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02407431
The ClinicalTrials.gov registry entry for NCT02407431 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 732-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (37% higher). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT02407431 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Pennsylvania, Maryland, Utah.
Frequently Asked Questions
What is clinical trial NCT02407431 about?
NCT02407431 is a clinical study titled "PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort". The purpose of the PaTH Network IPF Clinician-Patient Partnership Cohort is to use clinical data from electronic health records (EHR) and patient reported outcomes (PRO) to answer questions of clinical importance to patients with Idiopathic Pulmonary Fibrosis, providers, and other stakeholders.
What is the current status of trial NCT02407431?
This trial is currently active not recruiting. The enrollment target is 1,000 participants. The study started on 2015-03. Estimated completion is 2030-07.
What conditions does trial NCT02407431 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
Who is sponsoring clinical trial NCT02407431?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02407431 being conducted?
This trial has 5 study locations across Maryland, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.